30Jun
Healthcare M&A prospers, despite fall in deal activity
The megadeals of 2019 may be off the table for now, but deal activity across healthcare and pharmaceuticals has proven resilient through the COVID-19 crisis - Although pharma, medical and biotech (PMB) M&A deal value for Q1 2020 came in at US$39.3 billion, 78% below the year before, this was primarily due to the outsized US$87.8 billion deal between Bristol-Myers Squibb and Celgene in early 2019....
By:
White & Case LLP
Related
The California Legislature has passed Assembly Bill 5 (“AB 5”), which if signed by Governor Gavin ...
Read More >
This case arises out of plaintiff John B. Napoleone’s failure to repay a sign-on bonus of $100,000 ...
Read More >
In today’s edition of Daily Compliance News: • One of the country’s top border officers cannot s...
Read More >
What’s a New Mexico business to do if one of its key employees is absent from work due to a non-wor...
Read More >
I worked at a third-party administration (TPA) where one of our administrators tried to steal money ...
Read More >
The House and Senate both returned to Raleigh this week for a three-day session, pursuant to the adj...
Read More >